Cargando…
Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series
Background. Lennox–Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy (DEE) in which drug resistance to antiepileptic drugs (AEDs) is common. Focal-onset seizures (FOS) are among the seizure types characterizing LGS. Cenobamate (CNB) is a new AED indicated for the treatment of FO...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821211/ https://www.ncbi.nlm.nih.gov/pubmed/36614931 http://dx.doi.org/10.3390/jcm12010129 |
_version_ | 1784865643258970112 |
---|---|
author | Falcicchio, Giovanni Lattanzi, Simona Negri, Francesco de Tommaso, Marina La Neve, Angela Specchio, Nicola |
author_facet | Falcicchio, Giovanni Lattanzi, Simona Negri, Francesco de Tommaso, Marina La Neve, Angela Specchio, Nicola |
author_sort | Falcicchio, Giovanni |
collection | PubMed |
description | Background. Lennox–Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy (DEE) in which drug resistance to antiepileptic drugs (AEDs) is common. Focal-onset seizures (FOS) are among the seizure types characterizing LGS. Cenobamate (CNB) is a new AED indicated for the treatment of FOS and it has shown promising results in terms of seizure frequency reduction in both clinical trials and real-world experience. To date, the use of CNB in patients with DEEs is limited to Dravet syndrome. Methods: This was a retrospective study aimed to determine the 12-month effectiveness and tolerability of CNB in patients with LGS following real-world practice. Results: Four patients with LGS receiving CNB treatment were identified. At 12 months from starting CNB, the reduction in baseline seizure frequency ranged from 25 to 74%, with two patients achieving ≥50% seizure reduction. CNB was generally well tolerated and adjustments in doses of concomitant AEDs were required. Conclusions: CNB may represent a promising therapeutic option in patients with drug-resistant epilepsy associated with LGS. Further research is needed to confirm this preliminary evidence. |
format | Online Article Text |
id | pubmed-9821211 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-98212112023-01-07 Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series Falcicchio, Giovanni Lattanzi, Simona Negri, Francesco de Tommaso, Marina La Neve, Angela Specchio, Nicola J Clin Med Communication Background. Lennox–Gastaut syndrome (LGS) is a developmental and epileptic encephalopathy (DEE) in which drug resistance to antiepileptic drugs (AEDs) is common. Focal-onset seizures (FOS) are among the seizure types characterizing LGS. Cenobamate (CNB) is a new AED indicated for the treatment of FOS and it has shown promising results in terms of seizure frequency reduction in both clinical trials and real-world experience. To date, the use of CNB in patients with DEEs is limited to Dravet syndrome. Methods: This was a retrospective study aimed to determine the 12-month effectiveness and tolerability of CNB in patients with LGS following real-world practice. Results: Four patients with LGS receiving CNB treatment were identified. At 12 months from starting CNB, the reduction in baseline seizure frequency ranged from 25 to 74%, with two patients achieving ≥50% seizure reduction. CNB was generally well tolerated and adjustments in doses of concomitant AEDs were required. Conclusions: CNB may represent a promising therapeutic option in patients with drug-resistant epilepsy associated with LGS. Further research is needed to confirm this preliminary evidence. MDPI 2022-12-24 /pmc/articles/PMC9821211/ /pubmed/36614931 http://dx.doi.org/10.3390/jcm12010129 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Falcicchio, Giovanni Lattanzi, Simona Negri, Francesco de Tommaso, Marina La Neve, Angela Specchio, Nicola Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series |
title | Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series |
title_full | Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series |
title_fullStr | Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series |
title_full_unstemmed | Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series |
title_short | Treatment with Cenobamate in Adult Patients with Lennox–Gastaut Syndrome: A Case Series |
title_sort | treatment with cenobamate in adult patients with lennox–gastaut syndrome: a case series |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821211/ https://www.ncbi.nlm.nih.gov/pubmed/36614931 http://dx.doi.org/10.3390/jcm12010129 |
work_keys_str_mv | AT falcicchiogiovanni treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries AT lattanzisimona treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries AT negrifrancesco treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries AT detommasomarina treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries AT laneveangela treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries AT specchionicola treatmentwithcenobamateinadultpatientswithlennoxgastautsyndromeacaseseries |